Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

303

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

DRUG

SHR6508

SHR6508 will be administered to all the eligible subjects

Trial Locations (1)

Peking University People's Hospital, Beijing

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY